İnfantil Hemanjiomların Tedavisinde Güncel Yaklaşımlar

Yıl 2023, , 89 - 94, 27.03.2023

Aybüke Doğan Emine Ecem Aydoğan Hikmet Gülşah Tanyıldız

https://doi.org/10.26650/jchild.2023.878287

Öz

İnfantil hemanjiyom (İH), süt çocukluğu döneminin en sık görülen benign vasküler tümörüdür. Etyopatogenezi hakkında kesin bir bilgi olmamakla birlikte iki temel teoriden bahsedilebilir. Bu teorilerden en çok kabul göreni maternal hipoksik strese bağlı hipoksiyle indüklenen faktör 1 alpha (HIF1-α) artışının VEGF, GLUT1 ve insülin benzeri büyüme faktörü-2 düzeylerini arttırması ve bunun sonucunda endotelyal hücre proliferasyonunun indüklenmesidir. İkinci teori ise plasental doku embolizasyonu nedeniyle ortaya çıkan endotelyal hücre proliferasyonudur. Propranolol İH’nin güncel medikal tedavisinde birinci basamakta kullanılan bir non selektif beta adrenerjik reseptör blokeridir. Derlememizde propranololün etkinliği ve güvenilirliğini moleküler düzeyde yapılan araştırmaları da göz önünde bulundurarak güncel veriler ışığında sunmayı planladık

Anahtar Kelimeler

İnfantil hemanjiom, propranolol, topikal timolol

Current Approach to The Treatment of Infantile Hemangioma

Öz

Infantile hemangioma (IH) is the most common benign vascular tumor of the infantile period. Although the etiopathology of IH is not well-known, two primary theories exist. The most accepted theory suggests that maternal hypoxic stress leads to the production of hypoxia inducible factor-1 alpha (HIF-1a), which leads to an increased production of vascular endothelial growth factor (VEGF), GLUT-1, and insulin-like growth factor-2, which induces endothelial cell proliferation. The second theory suggests that endothelial cell proliferation is induced by embolization of placental tissue. Propranolol is a nonselective beta-adrenergic receptor blocker which is used in current mainstay therapy for IH. In this review, we aimed to discuss the efficacy and safety of propranolol in light of current data, including studies at the molecular level.

Anahtar Kelimeler

Infantile hemangioma, propranolol, topical timolol

Kaynakça

• 1. Metry D. Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications. In: UpToDate, Moise L Levy (Ed), Rosamaria Corona (Ed), 2020 UpToDate google scholar
• 2. Leaute-Labreze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 1;390(10089):85-94. google scholar
• 3. Smith CJF, Friedlander SF, Guma M, Kavanaugh A, Chambers CD. Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Res 2017;3;109(11):809-815. google scholar
• 4. Karakuş Y, Savran B, Dibeklioğlu S, Adıgüzel Ü, Öztürk T, Kaçar, H. Our complicated hemangiomas cases and propranolol therapy. Pamukkale Medical Journal 2016;9;23-27. google scholar
• 5. Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics 2019;143(1):e20183475. google scholar
• 6. Hagen R, Ghareeb E, Jalali O, Zinn Z. Infantile hemangiomas: what have we learned from propranolol? Curr Opin Pediatr 2018;30(4):499-504. google scholar
• 7. Huang J, Jiang D, Zhao S, Wang A. Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression. Anticancer Drugs 2019;30(5):501-507. google scholar
• 8. Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998;101(3 Pt 1):446-52. google scholar
• 9. Leaute-Labreze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017;1;390(10089):85-94. google scholar
• 10. Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY. et al. Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. JAMA Dermatol 2017;1;153(6):529-536. google scholar
• 11. Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis. Pediatrics 2016; 137(2):e20153896. google scholar
• 12. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 19;372(8):735-46. google scholar
• 13. Ji Y, Chen S, Wang Q, Xiang B, Xu Z, Zhong L. et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep 2018; 9;8(1):4264. google scholar
• 14. Stringari G, Barbato G, Zanzucchi M, Marchesi M, Cerasoli G, Tchana B, et al. Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. Pediatr Med Chir 2016;27;38(2):113. google scholar
• 15. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131(1):128-40. google scholar
• 16. Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G, et al. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics 2016;138(4):e20160353. google scholar
• 17. Chang L, Lv D, Yu Z, Ma G, Ying H, Qiu Y, et al. Infantile hemangioma: factors causing recurrence after propranolol treatment. Pediatr Res 2018;83(1-1):175-182. google scholar
• 18. Zhang L, Wu HW, Yuan W, Zheng JW. Propranolol therapy for infantile hemangioma: our experience. Drug Des Devel Ther 2017;8;11:1401-1408. google scholar
• 19. Baselga E, Dembowska-Baginska B, Przewratil P, Gonzalez-Ensenat MA, Wyrzykowski D, Torrelo A, et al. Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma. Pediatrics 2018;142(3):e20173866. google scholar
• 20. Ji Y, Chen S, Wang Q, Xiang B, Xu Z, Zhong L, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep 2018;9;8(1):4264. google scholar
• 21. Frongia G, Byeon JO, Mehrabi A, Günther P. Recurrence rate of infantile hemangioma after oral propranolol therapy. Eur J Pediatr 2021;180(2):585-590. google scholar
• 22. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 2013;131(6):e1739-47. google scholar
• 23. Qiao J, Lin J, Zhang D, Li J, Chen C, Yu H, et al. Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2020;8;11:554847. google scholar
• 24. İstanbul Üniversitesi İstanbul Tıp Fakültesi Çocuk Hematoloji ve Onkoloji Bilim Dalı Arşivi. google scholar